NCT06762769 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06762769
Title	Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma (MODIFY)
Acronym	MODIFY
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	University College, London
Indications	smoldering myeloma
Therapies	Iberdomide + Isatuximab Dexamethasone + Iberdomide + Isatuximab
Age Groups:	senior \| adult
Covered Countries	GBR

Facility	Status	City	State	Zip	Country	Details
Barts Health Trust	RECRUITING	London		EC1A 7BE	United Kingdom	Details
Nottingham City Hospital	RECRUITING	Nottingham		NG5 1PB	United Kingdom	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06762769Clinical Trial Detail